1. Home
  2. News
  3. Alterity Therapeutics Ltd.
  4. New US patent for compounds to treat neurodegeneration
More Alterity Therapeutics Ltd. news
Alterity Therapeutics Ltd.ASX: ATH

New US patent for compounds to treat neurodegeneration

Dec 29, 2022 at 1:17 AM EST · Issued by Alterity Therapeutics Ltd.

Filed with ASX · Dec 29, 2022 at 1:17 AM EST · 3 pages · English

On 6ix: 6ix.com/news/new-us-patent-for-compounds-to-treat-neurodegeneration

Alterity Therapeutics Ltd. on 6ix

Story so far

  • US FDA Approval for IND Application for ATH434 for MSASep 20, 2022
  • Regulatory Approval to Proceed with Phase 2 Trial in ItalyJun 23, 2022
  • New US Patent Expands Neurodegeneration Treatment PortfolioAug 4, 2021

Earlier from Alterity Therapeutics

  • ATH434 Clinical Trial launched in AustraliaOct 13, 2022
  • US FDA Approval for IND Application for ATH434 for MSASep 19, 2022
  • Appendix 4E & Annual Report 2022Aug 31, 2022
  • ATH434 Phase 2 clinical launched in EuropeAug 25, 2022
  • First Patient dosed in ATH434 Phase 2 Clinical TrialJul 6, 2022

Later from Alterity Therapeutics

  • ATH434 clinical trial launched in the USJan 9, 2023
  • ATH434 Clinical Trial Launched in ItalyJan 24, 2023
  • Regulatory approval for Phase II trial in France and AustriaFeb 16, 2023
  • First Patient Enrolled in Europe in Phase II Clinical trialMar 7, 2023
  • US patent grant and license agreementMar 14, 2023
All Alterity Therapeutics news releases↗

Follow Alterity Therapeutics into a list and get an email when it puts out news.

Follow Alterity Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer